Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to… (NCT05964647) | Clinical Trial Compass
CompletedPhase 1
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
Switzerland20 participantsStarted 2024-02-01
Plain-language summary
The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any drug effect) compared to administration of LSD (150 µg) alone
Who can participate
Age range25 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 25 and 65 years
✓. Sufficient understanding of the German language
✓. Understanding of procedures and risks associated with the study
✓. Willing to adhere to the protocol and signing of the consent form
✓. Willing to refrain from the consumption of illicit psychoactive substances during the study
✓. Abstaining from xanthine-based liquids and foods from the evenings prior to the study sessions to the end of the study days, limit coffee drinking ≤ 3 cups per day for 7 days prior to study day
✓. Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration
✓. Willing to use effective contraceptive measures throughout study participation (according to Clinical Trial Facilitation Group (CTFG): Recommendations related to contraception and pregnancy testing in clinical trials)
Exclusion criteria
✕. Chronic or acute medical condition
✕. Current or previous major psychiatric disorder including psychotic disorder, mania / hypomania, borderline personality disorders.
✕. Psychotic disorder or bipolar disorder in first-degree relatives
✕. Known hypersensitivity to LSD, ketanserin, olanzapine or lorazepam